Improved method for manufacturing freeze dried dosages in a multilaminate blister pack
10 claims: 1 independent, 9 dependent
- 1A method for manufacturing freeze dried dosage forms in a blister pack, comprising:a) introducing liquid dosages into the depressions of a multilayer laminated blister film, the film comprising first and second outer layers and an impermeable intermediate layer positioned between the first and second outer layers, the first and second outer layers having substantially similar coefficients of thermal expansion;b) freezing the dosages;c) freeze drying the dosages and d) attaching a lidding sheet to the blister film to seal the dosages in the depressions of the blister film.
10 paragraphs, as filed
This invention relates generally to the field of manufacturing and dispensing pharmaceuticals, and more particularly to an improved method for manufacturing freeze dried pharmaceutical tablets in disposable single dose aluminum blister packs.
In recent years, pharmaceutical producers have turned to the use of blister packs for use in both the forming and dispensing of pharmaceutical tablets. These blister packs generally consist of a blister sheet or blister film and a lidding sheet. The blister sheet contains depressions for containing individual dosages. In a standard process for manufacturing freeze dried tablets, a single dosage, in liquid form, is introduced into each depression of the blister sheet. The blister sheet, along with the liquid dosages, is then placed into a refrigerated environment where the dosages are subjected to low temperatures to freeze them. The blister sheets are then transferred to a freeze drier, where the ice is removed by sublimation. When freeze drying is completed, the sheets are removed from the drying chamber and covered with an adhesive lidding sheet, which seals the solid dosages into their individual depressions. United States Patent No. 4,305502 is incorporated herein by reference as teaching, <u>inter alia</u>, a known process for manufacturing freeze dried tablets.
Blister sheets that have heretofore been used in freezing and freeze drying processes have suffered from several deficiencies. First, the blister sheets have typically been made of a polymeric substance, which, over time, can allow moisture to permeate the blister pack and reach the dosages stored inside. To solve this problem, blister sheets have been developed in which a layer of aluminum is laminated between layers of polymer. While the presence of the aluminum layer prevents moisture from permeating the blister pack, it leads to a second problem. Namely, when subjected to temperature changes during the freezing process, conventional aluminum/polymer laminates tend to curl up, due to the differences in the degree of thermal expansion or contraction of the opposing layers of the laminate. This makes their use in freezing processes difficult, since liquid product can easily spill from the formed depressions or can lie unevenly in the depressions during filling and freezing operations. Furthermore, the curling of the blister sheet can cause dosages to freeze or sublimate unevenly, since some depressions may not be in physical contact with the cold surfaces of the refrigerator or freeze drier. The only solution has been to use weights on the edges of the laminate strips to hold them sufficiently flat. Such measures are not practical in large scale manufacturing operations, and can interfere with the freezing process.
A need therefore exists for a method of utilizing a high barrier aluminum laminate in the manufacture of freeze dried dosage forms that avoids the problem of curling of the blister sheet. The present invention is therefore directed to a method for manufacturing freeze dried dosage forms in a blister pack in which liquid dosages are introduced into depressions found in a blister film and then frozen. The dosages are then freeze dried and thereafter a lidding sheet is attached to the film to seal the dosages in the depressions. According to the invention, the blister film is laminated, and comprises first and second outer layers and an impermeable intermediate layer positioned between the first and second outer layers, the first and second outer layers having substantially similar coefficients of thermal expansion. The intermediate layer is typically aluminum
The properties of the outer layers of the laminate forming the blister film in methods of the invention are such that there are no inter-layer stresses that will cause curvature of the laminate when it is subjected to temperature changes during the freeze drying process. The symmetrical response of the outer layers to such temperature changes can be achieved by using the same film material for both outer layers, or by using different materials which, by virtue of their intrinsic properties or thickness, exhibit similar degrees of thermal expansion or contraction. The outer layers can each consist of separate sublayers, as long as the sublayers in one outer layer are such that the outer layer, as a whole exhibits the same overall degree of expansion or contraction as the other outer layer.
The invention will now be described by way of example and with reference to the accompanying drawings wherein: <ul id="ul0001" list-style="none" compact="compact"><li>Figure 1 of the drawing is a plan view of a blister sheet, showing the configuration of the dosage depressions;</li><li>Figure 2 of the drawing is a transverse cross sectional view of said blister pack, taken generally along the line 2--2;</li><li>Figure 3 of the drawing is a cross sectional view of a blister sheet illustrating in further detail the relationship between the intermediate and outer layers of the blister sheet;</li><li>Figure 4 of the drawing is a cross sectional view of a blister sheet illustrating in further detail the relationship between the various layers and sublayers of the blister sheet;</li><li>Figure 5 of the drawing is a cross sectional view of a blister pack with the lidding sheet in place.</li></ul>
In the blister pack shown in Figure 1 and Figure 2, depressions 10 are formed in a strip 12 of the desired laminate through conventional cold forming. The size and shape of the depressions is a matter of choice that will be dictated by the size and nature of the tablet to be formed, as well as other considerations that are well known to those persons skilled in the art.
Turning to Figure 3, the laminate strip 12 comprises an intermediate layer 14 that is substantially impermeable to moisture. The preferred material for the intermediate layer is aluminum having a thickness of 10 to 100µm, with the preferred thickness being approximately 45µm, although other suitable materials may be used in its place. The intermediate aluminum layer 14 is sandwiched between a first outer layer 16 and a second outer layer 18. The outer layers may be coated or laminated onto the intermediate layer, but the layers do not necessarily have to be bonded together. The first and second outer layers are preferably made of polymeric substances, including polyamide, polyvinylchloride, polypropylene or other such substances. The first and second outer layers can be made of the same or different materials, and may have different thicknesses, as long as they have substantially similar coefficients of thermal expansion, i.e., are made of such materials and have such thickness that the first and second outer layers exhibit substantially the same degree of expansion or contraction within the plane of the film when the laminate is subjected to changes in temperature, particularly within the range of temperatures encountered during the freezing process, in which temperatures can be as low as -196°C. For instance, the laminated film 12 can consist of an intermediate layer 14 of aluminum, positioned between first and second outer layers of polypropylene 16 and 18, each layer being approximately 50µm thick.
Turning to Figure 4, it can be seen that one or both of the outer layers can also consist of separate sublayers, with each sublayer being either polymeric or nonpolymeric. For instance, the first outer layer 16 can consist of two or more sublayers, such as a polyamide sublayer 20 and a polyvinylchloride sublayer 22. The second outer layer 18 can consist of a identical sublayers, or can also consist of two or more sublayers, illustrated as 24, 26 and 28, that are different than the sublayers in the first outer layer 16. Materials that may be used as sublayers include the above mentioned polymers, as well as lacquer, aluminum or paper. A priming layer can also be included. Again, the primary concern is that the first outer layer 16 and the second outer layer 18 exhibit, overall, substantially the same degree of expansion or contraction in response to temperature changes, so as to prevent curling of the blister sheet.
Returning to Figure 1, a single dosage 30 of pharmaceutical, in liquid form, is introduced into each depression in the blister sheet in a conventional manner. The blister sheet is then placed into a refrigeration unit, for instance a nitrogen spray freezing chamber, where both the sheet and the dosages are subjected to temperatures sufficient to rapidly freeze the dosages, typically as low as -196°C. Once the dosages have frozen, the blister sheet is transferred to a freeze drying chamber. Within the freeze drying chamber, the dosages are subjected to a vacuum of typically 0.1 to 1.0 mBar for a period of 180 to 500 minutes. At the same time, the temperature is steadily increased from typically about -30°C to about 60°C. As shown in Figure 5, once the dosages have been freeze dried, an adhesive lidding sheet 32 is positioned over the blister sheet, sealing the dosages into the individual depressions of the blister sheet. The procedures associated with the introduction of dosages into the blister sheet, the freezing and freeze drying of the dosages and the attachment of the lidding sheet are known to persons to skill in the art, and need not be treated in great depth herein.
1 sheet
Sheet 1
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US6890472B2 | Cited by | United States of America | Search report |
| US7121822B2 | Cited by | United States of America | Applicant |
| EP0286407A | Cites | European Patent Office (EPO) | – |
| EP0389207A | Cites | European Patent Office (EPO) | – |
| US4150744A | Cites | United States of America | – |
| US4305502A | Cites | United States of America | – |
| US5014851A | Cites | United States of America | – |
43 members in 18 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 985040 | United States of America | – | |
| 98504092 | United States of America | A | |
| 98504092 | United States of America | A | |
| 9302459 | United Kingdom | W | |
| 9302459 | United Kingdom | W | |
| 985040 | – | – | – |
| GB9302459 | – | – | – |
| US19920985040 | – | – | – |
| WO1993GB02459 | – | – | – |
Members43
| Document | Office | Kind | |
|---|---|---|---|
| CA2129254A1 | Canada | A1 | |
| WO9412142A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU5654594A | Australia | A | |
| CN1089829A | China | A | |
| FI943537A | Finland | A | |
| NO942805D0 | Norway | D0 | |
| NO942805L | Norway | L | |
| US5343672A | United States of America | A | |
| HU9402091D0 | Hungary | D0 | |
| KR950700046A | Republic of Korea | A | |
| EP0646367A2 | European Patent Office (EPO) | A2 | |
| EP0646367A3 | European Patent Office (EPO) | A3 | |
| HUT69435A | Hungary | A | |
| JPH07508676A | Japan | A | |
| NZ258600A | New Zealand | A | |
| EP0710101A1 | European Patent Office (EPO) | A1 | |
| JPH08187271A | Japan | A | |
| JP2568479B2 | Japan | B2 | |
| BR9305805A | Brazil | A | |
| AU677030B2 | Australia | B2 | |
| EP0646367B1 | European Patent Office (EPO) | B1 | |
| AT153530T | Austria | T | |
| ATE153530T1 | Austria | T1 | |
| DE69311109D1 | Germany | D1 | |
| ES2102143T3 | Spain | T3 | |
| DE69311109T2 | Germany | T2 | |
| GR3023853T3 | Greece | T3 | |
| US5729958A | United States of America | A | |
| EP0710101B1This record | European Patent Office (EPO) | B1 | |
| AT165730T | Austria | T | |
| ATE165730T1 | Austria | T1 | |
| NO303161B1 | Norway | B1 | |
| DE69318429D1 | Germany | D1 | |
| DE69318429T2 | Germany | T2 | |
| JP2796578B2 | Japan | B2 | |
| ES2118368T3 | Spain | T3 | |
| HK1007489A1 | Hong Kong, China | A1 | |
| HU216509B | Hungary | B | |
| HK1013245A1 | Hong Kong, China | A1 | |
| KR100227315B1 | Republic of Korea | B1 | |
| CA2129254C | Canada | C | |
| FI105149B | Finland | B | |
| CN1066937C | China | C |
58 legal events, as 9 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Right expiredExpiredMA | MA | GR | |
| Ep patent has lapsedLapsedEUG | EUG | SE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expiredExpiredMK9A | MK9A | IE | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Patent ceasedCeasedPL | PL | CH | |
| Discontinued because of reaching the maximum lifetime of a patentV4 | V4 | NL | |
| Expiry of rightR071 | R071 | DE | |
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| New agentNV | NV | CH | |
| Name/firm changedPFA | PFA | CH | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Name/firm changedPFA | PFA | CH | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| European patents granted designating irelandGranted80220FG4D | FG4D | IE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Corresponds to:REF | REF | EP | |
| Fr: translation filedET | ET | EP | |
| New agentNV | NV | CH | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Corresponds to:REF | REF | EP | |
| Miscellaneous (additional remarks)TEILANMELDUNG 94203739.1 EINGEREICHT AM 30/11/93.XX | XX | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Despatch of communication of intention to grantORIGINAL CODE: EPIDOS AGRAGRAG | GRAG | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Despatch of communication of intention to grantORIGINAL CODE: EPIDOS AGRAGRAG | GRAG | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Miscellaneous (additional remarks)TEILANMELDUNG 94203739.1 EINGEREICHT AM 30/11/93.XX | XX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0710101
- Publication, DOCDB
- 0710101
- Publication, EPODOC
- EP0710101
- Application
- 94902027
- Application, DOCDB
- 94902027
- Application, EPODOC
- EP19940902027
Titles3
- German
- METHODE ZUR HERSTELLUNG VON GEFRIERGETROCKNETEN DOSIERUNGEN IN EINER BLISTERPACKUNG AUS MULTILAMINAT
- English
- IMPROVED METHOD FOR MANUFACTURING FREEZE DRIED DOSAGES IN A MULTILAMINATE BLISTER PACK
- French
- PROCEDE PERFECTIONNE DE PREPARATION DE DOSES LYOPHILISEES DANS UN EMBALLAGE MULTI-COUCHE ALVEOLAIRE
Classification
- CPC, 14
- A61J1/035
- A61J1/00
- B32B15/08
- A61K9/2095
- B32B27/06
- B65D75/327
- A61K9/20
- B32B15/20
- B32B1/00
- B32B2439/80
- B32B27/304
- B32B27/34
- B32B27/32
- B32B27/08
- IPC, 14
- B65B9 04
- A61J1 03
- A61J1 05
- A61J3 00
- A61K9 14
- A61K9 19
- A61K9 20
- B32B1 00
- B32B7 02
- B32B15 08
- B32B27 06
- B65D65 40
- B65D75 34
- B65D75 36
Designated states1
- Contracting states, 1
- Sweden
